Position of the Transparency Council – Edarabid (edarawon)
At its meeting on 9 June 2025, the Transparency Council adopted position No. 71/2025 on the validity of granting approval for reimbursement of the medicinal product Edarabid (edarawon) for the indication: amyotrophic lateral sclerosis.